The device focuses on examining sonoporation-based drug delivery that involves ultrasound-based treatment with microbubbles.

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 ...

Abbott neuromodulation medical director Allen Burton said: "Research shows treating CRPS with targeted DRG neurostimulation results in significantly better outcomes in terms of pain relief and ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a buy with a price target of $145-$160.

Wavegate Corporation, a company that makes neuromodulation technology for chronic pain management, has secured $26 million in a Series A funding round led by UCEA Capital Partners Ltd. WHAT IT DOES ...

Abbott’s neuromodulation medical director says the company’s spinal cord stimulator, which won gold at the 2025 Edison Awards, is small but mighty.

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

For people with treatment-resistant depression, traditional medicines and therapy have failed, but Abbott hopes deep brain stimulation can help.

Abbott (ABT) announced Thursday that the FDA approved expanded MRI labeling for its pain relief device Eterna spinal cord stimulation ((SCS)) system. Read more here.

Abbott Laboratories ABT has been delivering consistent organic growth in the Established Pharmaceuticals Division (EPD) and Diabetes segments. However, the soft neuromodulation business is a ...

Abbott's NeuroSphere Virtual Clinic gives patients the flexibility and comfort of receiving care anywhere. The new system allows patients implanted with an Abbott neuromodulation device to ...